GRANGER, STEWART PATON,SCOTT, IAN RICHARD,IOBST, SUSANNE TEKLITS,LICAMELI, LISA,DONOVAN, ROBERT MARK
申请号：
ES01957886
公开号：
ES2524559T3
申请日:
2001.06.25
申请国别(地区):
ES
年份:
2014
代理人:
摘要：
A skin care composition, comprising: a. from 0.001% to 10% by weight of the composition of a retinoid； b. a combination of at least 4 retinoid reinforcements belonging to the classes of LRAT / ARAT (B1) inhibitors, retinol dehydrogenase (B2) agonists, retinal reductase (B3) inhibitors, CRABP-2 (B4) agonists and inhibitors of the oxidation of cytochrome retinoic acids (B5) in an amount of 0.0001% to 50% by weight of the composition, in which the proportions of each of the reinforcements with each other is in the range of 1: 1000 to 1000: 1； C. a pharmaceutically acceptable vehicle. wherein the LRAT / ARAT (B1) inhibitor is selected from the group consisting of crocetin, sphingosine acetyl, cocamidopropyl betaine, coconut hydroxyethyl-imidazoline, cocoamide-mea, glycerol-pca-oleate, hexanoamide, sphingosine hexanoyl, lauroyl sarcosine , lidocaine, linoleamidedea, linoleamide-mea, dimethylamine linoleamidopropyl, melinamide, myristoyl sarcosine, oleyl betaine, palmitamide-mea, stearylhydroxyamide, naringenin, allyl alpha-ionone, alpha-damascone, alpha-ionone, alpha-methyl ionone, alpha-betaineol, alpha -damascona, brahmanol, damascenone, delta damascona, dihydro alpha-ionone, ethyl safranate, phenyl alcohol, gamma-methyl ionone, isobutyl ionone, isocyclogeraniol, isodamascone liral, santalone, santanol, timberol, tonalid, trasmol, coconut trimethylammonium chloride, ursolic acid, citral, citronellol, farnesol, geraniol, geranyl geraniol, linalool, nonadieneal, pseudoionone, dioctylphosphatidyl ethanolamine, dimethyl imidazolidinone and imidazolidinyl urea； wherein the retinol dehydrogenase (B2) agonist is selected from the group consisting of phosphatidylcholine and sphingomyelin； wherein the retinaldehyde reductase inhibitor (B3) is selected from the group consisting of vanillin, arachidic acid, arachidonic acid, linoleic acid, linolenic acid, myristic acid, amsacrine, carbenoxolone, glycyrethrinic acid and phosphatidylethanolamine； wherein the CRABP-2 (B4) antagonist
